



Corporate Information - A Snapshot

- ▶ Aurobindo Pharma Limited based at Hyderabad, India manufactures generic pharmaceuticals and Active Pharmaceutical Ingredients. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment.
- ▶ One of the world's top 5 manufacturers of semi synthetic penicillins.
- ▶ Has Asia's largest sterile API facility.
- ▶ One of India's top 5 pharma companies ranked in terms of turnover.
- ▶ Aspires to become a leading provider of generic Pharmaceuticals.
- ▶ 14 manufacturing plants across the world conforming to GMP / ISO regulations and an extremely well equipped R&D facility.
- ▶ Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo's 6 units for APIs and 3 units for formulations are designed for the regulated markets.
- ▶ The Company received 45 product approvals from US FDA for marketing in the USA and many more are under approval.
- ▶ The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings.
- ▶ Significant number of Abbreviated New Drug Applications (ANDA) has been filed, of which 82 are with the US FDA and 26 in European Union. Approvals for marketing have been received for 45 products from the US FDA, five from UKMHRA and one from EDQM.
- ▶ Aurobindo has really geared up in the ARV segment and under PEPFAR programme has received approvals for eighteen products and also registered ARV products with WHO and other countries like South Africa.

- ▶ The World Health Organization (WHO), Geneva, has also approved Aurobindo's products. The Company is increasing its presence in PEPFAR programme and hopes to consolidate its position further.
- ▶ Has a large infrastructure for developing innovative technologies, creating an intellectual property knowledge base in chemical synthesis and drug delivery systems.
- ▶ Excellent facilities for manufacture of speciality generic formulations.
- ▶ US FDA has approved seven manufacturing units of the company, covering APIs and formulations. Medicines and Healthcare products Regulatory Agency, UK (UK MHRA), MCC South Africa, Health Canada, Brazil Anvisa have approved three production facilities.
- ▶ Versatile product mix including antibiotics, antivirals, antidepressants, antifungals, cardiovasculars, macrolides etc.
- ▶ Around 60% of sales volume contributed through exports out of India, to over 100 countries.
- ▶ Sales offices / Joint Ventures / Subsidiaries/ Warehouses at strategic global locations.
- ▶ Estimated sales of US\$ 500 million in the present financial year.
- ▶ An enviable list of clientele across the globe.
- ▶ The net worth of the Company stood at Rs.9.78 billion as at March 31, 2006, a growth of over 71% in three years.